Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (171-180 of 266) with videos related to

Pageof 27
Sort By:
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunityHong Yu, Hiroshi Nishio, Joseph Barbi, et al.
Cancer Immunology Research|August 6, 2016
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell CarcinomaMaria Libera Ascierto, Tracee L McMiller, Alan E Berger, et al.
Cancer Immunology Research|February 24, 2018
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic TumorsBrian J Francica, Ali Ghasemzadeh, Anthony L Desbien, et al.
The Prostate|February 26, 2021
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trialEugene Shenderov, Karim Boudadi, Wei Fu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2014
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialBora Gurel, M Scott Lucia, Ian M Thompson, et al.
Communications Medicine|July 2, 2024
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistanceYu-Hwa Huang, Charles H Yoon, Amit Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional AnalysesDavid H Aggen, Casey R Ager, Aleksandar Z Obradovic, et al.
Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.
Blood|March 30, 2007
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsMonica V Goldberg, Charles H Maris, Edward L Hipkiss, et al.
Pageof 27

Showing results (171-180 of 266) with videos related to

Sort By:
Pageof 27
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunityHong Yu, Hiroshi Nishio, Joseph Barbi, et al.
Cancer Immunology Research|August 6, 2016
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell CarcinomaMaria Libera Ascierto, Tracee L McMiller, Alan E Berger, et al.
Cancer Immunology Research|February 24, 2018
TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic TumorsBrian J Francica, Ali Ghasemzadeh, Anthony L Desbien, et al.
The Prostate|February 26, 2021
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trialEugene Shenderov, Karim Boudadi, Wei Fu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2014
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialBora Gurel, M Scott Lucia, Ian M Thompson, et al.
Communications Medicine|July 2, 2024
High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistanceYu-Hwa Huang, Charles H Yoon, Amit Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional AnalysesDavid H Aggen, Casey R Ager, Aleksandar Z Obradovic, et al.
Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.
Blood|March 30, 2007
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsMonica V Goldberg, Charles H Maris, Edward L Hipkiss, et al.
Pageof 27